HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lutein Drove Recent Supplement Growth; Single Herbs Stayed Flat – Study

This article was originally published in The Tan Sheet

Executive Summary

The inclusion of lutein in multivitamins almost single-handedly propelled an increase in dietary supplement use since the late 1990s, according to a study in the Feb. 14 Archives of Internal Medicine

You may also be interested in...



St. John's wort

Thirty-nine of 472 SJW-related adverse event reports submitted to FDA through Dec. 11, 2000 indicated "possible" pharmacokinetic interactions with substrates of P450 CYP3A and/or p-glycoprotein (cyclosporin, levonorgestrel/ estradiol and sildenafil) as well as serotonin reuptake inhibitors, according to agency researchers. AERs show SJW may result in exaggerated hypertensive reactions when taken with SSRIs and "decrease expected effect" of the three drugs, but researchers stress "additional studies are needed to assess mechanistic issues and the full spectrum of clinical implications arising from these interactions." FDA and NIH issued warnings on concomitant use of SJW supplements and protease inhibitors in early 2000 (1"The Tan Sheet" Feb. 14, 2000, p. 19)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel